Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China

Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li · 2026

Read Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China by Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13396110.txt.

Description

Yue Li and colleagues gathered records from six medical centers in China on 60 people with myasthenia gravis treated with eculizumab, a drug that blocks part of the immune system. Their 2026 real-world study fills a gap, since most proof for the drug comes from tightly run trials.

Charts yielded daily-living scores, strength scores, and steroid doses at the start, at weeks one, four, and eight, and at final follow-up. By week eight, about 31 percent had reached minimal symptoms or better, rising to about 33 percent at last check. Daily-living scores fell, and the authors also report steroid use and side effects over the course.

Catalog record

CREATORYue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51168
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13396110

Browse the full library · About the Tower of Babel